```html

Yeast Infection (Candida) of the Urinary Tract

Overview

Candida‑related urinary tract infection (UTI) occurs when the yeast Candida multiplies in the bladder, urethra, or kidneys. Although bacteria cause the majority of UTIs, Candida accounts for 5‑15 % of all urinary infections in hospitalized patients and up to 25 % of UTIs in people with indwelling catheters or severe immunosuppression.<sup>[1] Mayo Clinic</sup> The condition is sometimes called “candiduria” when Candida is detected in the urine, but true infection—meaning symptomatic disease—requires both the presence of yeast and clinical signs such as dysuria, frequency, or flank pain.

Anyone can develop candiduria, but it is most common in:

• Women (higher baseline prevalence of vaginal Candida)
• Individuals with diabetes mellitus
• Patients with long‑term urinary catheters or recent urinary stents
• People receiving broad‑spectrum antibiotics or chemotherapy
• Those with weakened immune systems (e.g., HIV, organ transplant recipients)

In the United States, an estimated 100,000–150,000 cases of candiduria are reported each year, with higher rates in intensive‑care units (ICUs).<sup>[2] CDC</sup>

Symptoms

Symptoms may be mild or absent, especially in catheterized patients, but typical complaints include:

• Dysuria: Burning or painful urination.
• Urinary frequency and urgency: A sudden need to void more often.
• Hematuria: Blood in the urine, usually microscopic.
• Cloudy or foul‑smelling urine: May have a “yeasty” odor.
• Flank or abdominal pain: Suggests upper‑tract involvement (kidney).
• Fever, chills, or malaise: Often indicate a more serious infection or spread to the bloodstream.
• Pelvic pressure or discomfort: Especially in women.

In some patients, the infection is discovered incidentally on a routine urine culture without any symptoms. This distinction is important because asymptomatic candiduria often does not require treatment unless the patient is high‑risk (e.g., neutropenic, undergoing urologic surgery).

Causes and Risk Factors

How Candida Invades the Urinary Tract

Candida species are normal flora of the gastrointestinal and genitourinary tracts. Overgrowth can occur when:

• Normal bacterial competitors are suppressed by antibiotics.
• The immune system is unable to control yeast proliferation.
• There is a direct route for yeast to enter the bladder (e.g., via a catheter or from the perineum).

Key Risk Factors

• Indwelling urinary catheters: Provide a surface for biofilm formation; risk rises after 48 hours of catheterization.
• Diabetes mellitus: High glucose in urine promotes yeast growth; poorly controlled diabetes triples the risk.<sup>[3] NIH</sup>
• Broad‑spectrum antibiotics: Disrupt normal bacterial flora, allowing Candida to flourish.
• Immunosuppression: HIV/AIDS, chemotherapy, corticosteroids, organ transplantation.
• Urinary tract abnormalities: Obstruction, stones, or congenital malformations.
• Recent urinary procedures: Cystoscopy, urodynamic studies, or stent placement.
• Pregnancy: Hormonal changes and increased glucose excretion raise susceptibility.
• Female gender: Shorter urethra facilitates ascent of organisms.

Diagnosis

Accurate diagnosis combines clinical evaluation with laboratory testing.

1. Urine Culture

Two consecutive clean‑catch midstream specimens showing ≥10<sup>3</sup> colony‑forming units (CFU)/mL of Candida is the gold standard. C. albicans accounts for 70‑85 % of isolates; non‑albicans species (e.g., C. glabrata, C. tropicalis) are increasingly reported.

2. Microscopy

Wet mount or Gram stain may reveal yeast buds or pseudohyphae, supporting infection but not distinguishing colonization from disease.

3. Sensitivity Testing

Because non‑albicans species can be fluconazole‑resistant, an antifungal susceptibility panel guides therapy when systemic treatment is considered.

4. Imaging (if upper‑tract involvement suspected)

• Renal ultrasonography or CT abdomen/pelvis to assess for obstruction, abscess, or pyelonephritis.

5. Blood Cultures

Indicated when the patient is febrile, immunocompromised, or shows signs of systemic infection; candidemia occurs in 5‑10 % of patients with candiduria and carries a high mortality rate.

Treatment Options

Treatment decisions hinge on symptom severity, patient risk profile, and Candida species.

1. When to Treat

• Symptomatic candiduria (dysuria, frequency, flank pain, fever).
• Patients undergoing urologic surgery, especially involving prosthetic devices.
• Neutropenic patients (absolute neutrophil count <500 cells/µL).
• Pregnant women (to prevent ascending infection).

Asymptomatic patients without the above risk factors often do not require antifungal therapy; removing or replacing catheters may be sufficient.

2. Antifungal Medications

Drug	Typical Dose	Route	Comments
Fluconazole	200‑400 mg loading, then 100‑200 mg daily	Oral or IV	Most effective for C. albicans; dose adjusted for renal function.
Amphotericin B (deoxycholate)	0.3‑0.6 mg/kg/day	IV	Reserved for fluconazole‑resistant species or severe infection; nephrotoxic.
Echinocandins (caspofungin, micafungin, anidulafungin)	70‑100 mg loading, then 50‑70 mg daily	IV	Effective against most non‑albicans species; not first‑line for uncomplicated cystitis.
Flucytosine	2.5‑5 mg/kg q6h	Oral/IV	Often combined with amphotericin B for synergistic effect.

Typical treatment duration is 7–14 days for uncomplicated cystitis; 14–21 days for pyelonephritis or when a catheter cannot be removed immediately.

3. Catheter Management

• Remove or replace indwelling catheters as soon as feasible.
• If catheter must remain, change it every 48‑72 hours and consider antiseptic‑impregnated catheters.

4. Adjunctive Measures

• Optimize glycemic control in diabetics (target HbA1c <7 %).
• Limit unnecessary antibiotic use.
• Hydration: Aim for ≥2 L of urine output per day to flush organisms.

Living with Yeast Infection (Candida) of the Urinary Tract

Daily Management Tips

• Stay hydrated: Drink water regularly; dilute sugary drinks and caffeine.
• Maintain good perineal hygiene: Wash front to back, avoid harsh soaps, and dry thoroughly.
• Urinate after sexual activity: Helps clear organisms.
• Wear breathable underwear: Cotton fabrics reduce moisture build‑up.
• Monitor symptoms: Keep a diary of pain, frequency, or fever and report changes to your clinician.
• Adhere to medication schedule: Complete the full course even if you feel better.
• Manage diabetes diligently: Check blood glucose multiple times a day and follow your nutrition plan.

Follow‑up Care

Repeat urine cultures are generally recommended 48‑72 hours after completing therapy to ensure eradication, especially in high‑risk patients.

Prevention

• Catheter stewardship: Use catheters only when medically necessary and remove them ASAP.
• Antibiotic prudence: Avoid prolonged broad‑spectrum antibiotics; choose narrow‑spectrum agents when possible.
• Blood glucose control: Target fasting glucose <130 mg/dL.
• Hydration and bladder emptying: Encourage regular voiding; avoid holding urine for long periods.
• Probiotic consideration: Some studies suggest Lactobacillus supplementation may restore normal flora, though evidence is modest.<sup>[4] Cleveland Clinic</sup>
• Educate at‑risk groups: Patients with catheters or immunosuppression should receive written instructions on signs of infection.

Complications

If left untreated or inadequately treated, Candida UTIs can lead to:

• Ascending infection (pyelonephritis): Can cause permanent renal scarring.
• Candidemia: Bloodstream infection with a mortality rate of 30‑60 % in ICU patients.<sup>[5] WHO</sup>
• Obstructive uropathy: Fungal balls (mycetomas) may block ureters.
• Recurrence: Up to 25 % of patients experience repeat episodes within a year, especially if risk factors persist.

When to Seek Emergency Care

References

1. Mayo Clinic. Candiduria: Urinary Tract Yeast Infection. 2023.
2. Centers for Disease Control and Prevention. Antibiotic‑Associated Diarrhea & Candida Infections. 2022.
3. National Institutes of Health. Diabetes and Urinary Tract Infections. 2021.
4. Cleveland Clinic. Probiotics for Urinary Health: What the Evidence Shows. 2022.
5. World Health Organization. Invasive Candidiasis: Global Burden. 2020.

```